Insider Moves: Edgewise Therapeutics Sees Major Stock Transactions!

Tip Ranks
2025.11.14 02:03
portai
I'm PortAI, I can summarize articles.

Edgewise Therapeutics saw significant insider transactions on November 13, 2025, with Director Jonathan C Fox purchasing 10,700 shares and CSO Alan J Russell selling 100,000 shares. The company appointed Michael Nofi as CFO and reported a Q3 net loss of $40.7 million. JPMorgan raised its price target to $33. Despite positive events, the stock is high-risk due to its pre-revenue stage and increasing losses. TipRanks’ AI Analyst rates EWTX as Underperform.

New insider activity at Edgewise Therapeutics ( (EWTX) ) has taken place on November 13, 2025.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

In recent transactions involving Edgewise Therapeutics stock, Director Jonathan C Fox made a significant purchase by acquiring 10,700 shares valued at $199,341. On the other hand, CSO Alan J Russell executed a major sale, offloading 100,000 shares for a total of $2,112,000.

Recent Updates on EWTX stock

Edgewise Therapeutics has recently announced the appointment of Michael Nofi as the new Chief Financial Officer, succeeding Michael Carruthers. This leadership change comes as the company is advancing its late-stage clinical development and preparing for commercialization. Edgewise also reported its Q3 2025 financial results, highlighting a net loss of $40.7 million and increased R&D expenses, but emphasized a strong balance sheet with $563.3 million in cash and equivalents. The company is actively advancing its clinical trials, including the pivotal GRAND CANYON cohort for Becker muscular dystrophy and the Phase 2 CIRRUS-HCM trial for hypertrophic cardiomyopathy. Additionally, JPMorgan raised Edgewise’s price target to $33 from $30, based on revised epidemiology and diagnosis rate assumptions for hypertrophic cardiomyopathy, noting that nonobstructive cases are growing faster than obstructive ones. Despite positive corporate events and promising trial results, Edgewise’s stock is viewed as high-risk due to its pre-revenue stage and increasing losses.

Spark’s Take on EWTX Stock

According to Spark, TipRanks’ AI Analyst, EWTX is a Underperform.

Edgewise Therapeutics’ overall score reflects significant risks due to its pre-revenue stage and increasing losses. Positive corporate events, including substantial fundraising and promising trial results, offer growth potential. However, the bearish technical indicators and valuation challenges highlight the stock’s high-risk profile typical of early-stage biotech companies.

To see Spark’s full report on EWTX stock, click here.

More about Edgewise Therapeutics

YTD Price Performance: -21.68%

Average Trading Volume: 935,363

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.24B

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.